

I hereby certify that the correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Box AF, Washington, D.C. 20231 on

4-10-96
by Christina Borgeno

PATENT
Attorney Docket No. 12418-18-2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Vanitha Ramakrishnan, et al.

Serial No.: 08/258,283

Filed: June 10, 1994

For: INHIBITORY IMMUNOGLOBULIN
POLYPEPTIDES TO HUMAN PDGF
BETA RECEPTOR

Examiner: P. Gambel

Art Unit: 1806

Honorable Commissioner of Patents and Trademarks
Washington, D.C. 20231



**DECLARATION UNDER 37 C.F.R. 1.131
and
IN COMPLIANCE WITH In re Katz**

Sir:

We, Vanitha Ramakrishnan, Maria Amelia Escobedo and Larry J. Fretto, hereby declare as follows:

1. That Vanitha Ramakrishnan, Maria Amelia Escobedo and Larry J. Fretto are the co-inventors and co-applicants of patent application Serial No. 08/253, 440, filed on June 7, 1994 (the "Parent"), which is a file-wrapper-continuation of Serial No. 07/801,795, filed on December 2, 1991, describing immunoglobulin polypeptides that block binding of platelet-derived growth factor ("PDGF") to the platelet-derived growth factor receptor.

2. That Vanitha Ramakrishnan, Maria Amelia Escobedo and Larry J. Fretto are the co-authors of a publication entitled "A Novel Monoclonal Antibody Dependent on Domain 5 of the Platelet-Derived Growth Factor Beta Receptor Inhibits Ligand Binding and Receptor Activation", Growth Factors, (8):253-265 (1993); and that Joseph J. Seroogy, James E. Tomlinson and David L. Wolf are also named as co-authors on the publication. The contributions of the authors not named as inventors is as follows:

a) David L. Wolf made the molecular biological construct and used it to transfect cells to produce the antigen (extracellular domain of the PDGF beta receptor), as described in column 1, lines 1-23, on page 255 of the publication. David L. Wolf also immunized rabbits to produce rabbit polyclonal serum, as described in column 1, lines 31-34 on page 255 of the publication.

b) James E. Tomlinson characterized the antigen-expressing cell lines made by David L. Wolf, as described in column 1, lines 23-43 on page 255 of the publication.

This antigen was later used as the immunogen for the production of the monoclonal antibodies. James E. Tomlinson also characterized the rabbit polyclonal antibodies made by David L. Wolf. These antibodies were used to determine the recombinant expression of the modified extracellular PDGF beta receptor by Western blot analysis, as described in column 1, lines 28-31 on page 255 of the publication.

c) Joseph J. Seroogy performed the partial purification of the antigen (extracellular domain of the PDGF beta receptor) that was used to determine antibody titer in the ELISA, as described in column 2 on page 255 of the publication.

d) It is our belief that co-authors Joseph J. Seroogy, James E. Tomlinson and David L. Wolf are not co-inventors of the claimed subject matter of the present application.

The undersigned declare further that all statements made herein of their own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements are made with the knowledge that willful false statements, and the like so made, are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing hereon.

Dated: 31 Jan '96

Vanitha Ramakrishnan
Vanitha Ramakrishnan

Dated: 1/26/96

Maria A. Escobedo
Maria Amelia Escobedo

Dated: 2/7/96

Larry J. Fretto
Larry J. Fretto

